| Gene Symbol | SNCA |
| Full Name | Alpha-Synuclein |
| Chromosome | 4q22.1 |
| Protein Type | Structural Protein |
| Target Class | Structural Protein |
| Function | Immunotherapy targeting alpha-synuclein aggregates or small molecules preventing aggregation |
| Mechanism of Action | Immunotherapy targeting alpha-synuclein aggregates or small molecules preventing aggregation |
| Primary Expression | Substantia nigra, Cerebral cortex, Presynaptic terminals |
| Druggability | Medium (0.49) |
| Clinical Stage | Phase II |
| Pathways | Akt, Alpha-Synuclein, Autophagy, Cell Cycle, Epigenetic |
| UniProt ID | P37840 |
| NCBI Gene ID | 6622 |
| Ensembl ID | ENSG00000145335 |
| OMIM | 163890 |
| GeneCards | SNCA |
| Human Protein Atlas | SNCA |
| Associated Diseases | AD, ALI, ALS, ALZHEIMERS_DISEASE, Aging, Alpha-Synucleinopathies |
| Known Drugs/Compounds | RAPAMYCIN, Rna G-Quadruplex, Phosphatidic Acid, ASO, levodopa, rapamycin |
| Interactions | DRD2, HSPA1A, DNMT1, TLR4, FAM134B, LC3 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Neuronal Subtype-Specific Alpha-Synuclein Expressi |
| KG Connections | 2895 knowledge graph edges |
| Databases | GeneCardsHPASTRING |